Skip to main content
. Author manuscript; available in PMC: 2018 Dec 18.
Published in final edited form as: Dev Cell. 2017 Nov 2;43(6):673–688.e5. doi: 10.1016/j.devcel.2017.10.011

Figure 6. INK128 inhibits MTOR activities and HH signaling in the brain.

Figure 6

(A) INK128 suppressed the SAG-induced increase in GLI1, SMO, 4EBP1, and p-4EBP1 levels in GNPs in culture. Cells were treated for 24 h. (B) Oral gavage of INK128 to WT pups at P10 inhibited the phosphorylation of 4EBP1, RPS6, and AKT within 2 h and decreased the GLI1 and SMO levels within 6 h. (C, D) Administration of INK128 (0.2 mg/kg BW) at P10 decreased the high levels of GLI1 and SMO in the tumors of GFAP::Cre; Ptch1loxP/loxP mice by 24h. The bars show the fold changes in SMO and GLI1 levels in the tumors of GFAP::Cre; Ptch1loxP/loxP mice relative to those in vehicle-treated mice 24 h after treatment (mean ± SD, 4 mice per group). Each lane in panels B and C represents a mouse. *** P < 0.005.